OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

10069	Companies
205846	Keywords
136108	Articles
109147	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 05/28/2025 at 18:00, 9 months 26 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC over aandelenbezit volgens Belgische wetgeving. Bedrijf combineert therapeutische innovatie met klinisch onderzoekstechnologieën

Transparantiekennisgevingen Oxurion NV Biofarmaceutisch Bedrijf Belgische Wetgeving Atlas Special Opportunities II LLC
BRIEF

published on 05/22/2025 at 18:05, 10 months 1 day ago

Résultats de l'Assemblée Générale d'Oxurion

Actionnaires Assemblée Générale Titres Déclarations Prospectives Oxurion
BRIEF

published on 05/22/2025 at 18:05, 10 months 1 day ago

Results of the Oxurion General Meeting

Securities Shareholders Forward-looking Statements General Assembly Oxurion
PRESS RELEASE

published on 05/22/2025 at 18:00, 10 months 1 day ago

Oxurion kondigt resultaten aan van de Jaarlijkse Aandeelhoudersvergadering van 13 mei 2025
Oxurion NV hield succesvol zijn jaarlijkse aandeelhoudersvergadering op 13 mei 2025. Alle agenda-items werden goedgekeurd. Meer informatie beschikbaar op www.oxurion.com

Euronext Brussel Oxurion NV Aandeelhoudersvergadering Biofarmaceutisch België
PRESS RELEASE

published on 05/22/2025 at 18:00, 10 months 1 day ago

Oxurion Announces Results on the Annual Shareholders' Meeting of 13 May 2025
Oxurion NV held its annual shareholders' meeting on May 13, 2025, in Leuven, Belgium. Shareholders approved all agenda items. Find more on Oxurion's website

Biopharmaceutical Clinical Data Euronext Brussels Annual Shareholders' Meeting Oxurion NV
BRIEF

published on 05/20/2025 at 18:05, 10 months 3 days ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actions Transparence Biopharmaceutique Atlas Special Opportunities Oxurion
BRIEF

published on 05/20/2025 at 18:05, 10 months 3 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Actions Transparency Biopharmaceuticals Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 05/20/2025 at 18:00, 10 months 3 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding shareholding percentages falling below thresholds. Atlas Special Opportunities II LLC sold voting securities affecting percentages. Visit www.oxurion.com for more info

Belgium Oxurion NV Transparency Notifications Shareholding Percentages Biofarmaceutical Company
PRESS RELEASE

published on 05/20/2025 at 18:00, 10 months 3 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV received transparency notifications from Atlas Special Opportunities II, LLC regarding changes in share ownership per Belgian Transparency legislation. Oxurion is a biopharmaceutical company developing ophthalmic therapies

Biopharmaceutical Share Ownership Ophthalmic Therapies Oxurion NV Transparency Notifications
BRIEF

published on 05/16/2025 at 08:35, 10 months 7 days ago

Oxurion to Acquire Majority Stake in Axiodis CRO

Acquisition Revenue Growth Oxurion Axiodis CRO Clinical Biometrics

Accesswire

Published on 03/23/2026 at 22:40, 10 minutes ago

Troubadour Announces Withdrawal of Non-Brokered Private Placements
Published on 03/23/2026 at 22:30, 20 minutes ago

Gregory J. Leia Sells Shares in Waskahigan Oil & Gas Corp
Published on 03/23/2026 at 22:00, 50 minutes ago

Hillcrest Participates in APEC 2026 and Announces Shares for Debt Offering
Published on 03/23/2026 at 21:18, 1 hour 32 minutes ago

Amdocs Announces Appointment of Shimie Hortig to the Board of Directors Upon Shuky Sheffer's Retirement as Director and Chief Executive Officer
Published on 03/23/2026 at 14:05, 8 hours 45 minutes ago

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 22:05, 45 minutes ago

DeFi Technologies Provides Update on Timing of Annual Filings
Published on 03/23/2026 at 21:05, 1 hour 45 minutes ago

Abivax annonce ses résultats financiers pour l’exercice 2025 et fait le point sur l’avancement de ses activités
Published on 03/23/2026 at 21:05, 1 hour 45 minutes ago

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Published on 03/23/2026 at 21:00, 1 hour 50 minutes ago

Persistent Appoints Ruchi Kulhari as Executive Vice President - Enterprise Strategy & Execution
Published on 03/23/2026 at 20:55, 1 hour 55 minutes ago

Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable

Les Echos

Published on 03/23/2026 at 19:08, 3 hours 42 minutes ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 3 hours 42 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 4 hours 13 minutes ago

ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 5 hours 5 minutes ago

ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 5 hours 5 minutes ago

En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde

View all LES ECHOS COMFI WIRE